Biogen (BIIB)
(Real Time Quote from BATS)
$199.24 USD
-2.20 (-1.09%)
Updated Sep 20, 2024 10:08 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
BIIB 199.24 -2.20(-1.09%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Lilly Gets FDA Approval for Eczema Drug Ebglyss
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
Other News for BIIB
IGM Biosciences: Waiting For Godot
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Cautious Optimism Amidst Growth Deceleration and Rising Competition for Biogen
Biogen Board Appoints Two New Independent Directors